Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 463 across all filing types
Latest filing 2026-06-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a Korean “주식등의 대량보유상황보고서(일반)” detailing the shareholding situation, including number of shares, ownership percentages, related parties, and changes. This corresponds precisely to a major shareholding notification filing under Korean regulations. No broader report or announcement context applies; it is the report itself disclosing significant share ownership. Therefore, it is classified as Major Shareholding Notification (MRQ).
2026-06-10 Korean
[기재정정]사업보고서 (2025.12)
Annual Report Classification · 80% confidence The document is a Korean ‘사업보고서’ (business report) filed as a ‘정정신고’ (amendment) to correct the original annual business report. It contains full financial statements and corrected accounting tables, indicating it is not merely an announcement or link but the substantive annual report content. Under our taxonomy, this aligns with the Annual Report (10-K) category. FY 2025
2026-06-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean "임원·주요주주 특정증권등 소유상황보고서," which is an insider share ownership report submitted to the Financial Supervisory Commission and Korea Exchange. It details an executive’s personal securities holdings and a transaction (sale of 500 shares). This matches the definition of Director’s Dealing (insider trades by company directors/executives), not a general major shareholding threshold notice. Thus, classify as DIRS.
2026-06-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a statutory ‘임원·주요주주 특정증권등 소유상황보고서’ filed with the Securities and Futures Commission and Korea Exchange, detailing a director’s personal share ownership and changes (insider acquisition of 12,500 shares). This matches the “Director’s Dealing” category for insider transactions by executives. Thus, the correct classification is DIRS.
2026-05-22 Korean
[기재정정]주식매수선택권부여에관한신고
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory “신고” (disclosure) to the Financial Services Commission/Korea Exchange correcting a previously filed stock‐option grant notice. It does not present financial statements (ruling out IR/10-K/AR), nor is it a general meeting result (DVA), director trades (DIRS), dividend (DIV), or M&A (TAR). It is a specific compliance filing for a stock‐option grant correction, which does not fit into the other more substantive report categories. Hence it is classified as a general Regulatory Filing (RNS).
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 92% confidence The document is titled “분기보고서” and covers the period 2026-01-01 to 2026-03-31 for Chabiotech Co., Ltd. It includes detailed substantive sections (company overview, business activities, history, capital changes, subsidiaries, share capital, etc.). This is a full interim/quarterly financial report rather than just an announcement or summary. It therefore falls under the Interim / Quarterly Report category. Q1 2026
2026-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.